{"hands_on_practices": [{"introduction": "Safe contraceptive prescribing begins with a systematic assessment of patient-specific risks based on established evidence. This practice [@problem_id:4819644] challenges you to construct a decision algorithm based on the United States Medical Eligibility Criteria (USMEC), mapping common comorbidities to appropriate risk categories. Mastering this skill is fundamental to ensuring patient safety and providing guideline-concordant care.", "problem": "A clinician in internal medicine is designing a clinic protocol to guide contraceptive eligibility counseling that is consistent with the United States Medical Eligibility Criteria (USMEC) categories, which are defined as follows: Category $1$ (no restriction), Category $2$ (advantages generally outweigh theoretical or proven risks), Category $3$ (risks usually outweigh advantages), and Category $4$ (unacceptable health risk). The protocol must map four common comorbidities—hypertension, diabetes mellitus, venous thromboembolism (VTE, meaning deep vein thrombosis or pulmonary embolism), and cigarette smoking at age $\\geq 35$ years—to appropriate USMEC categories for combined hormonal contraception (CHC; estrogen-progestin) and the levonorgestrel intrauterine device (LNG-IUD).\n\nUse only fundamental, well-tested facts to construct the mapping: estrogen-containing methods increase hepatic production of clotting factors and raise risks of venous and arterial thromboembolism; progestin-only intrauterine methods have minimal systemic effects; vascular disease increases baseline risk for myocardial infarction and stroke; with hypertension, arterial event risk rises in proportion to the severity of blood pressure elevation; with diabetes mellitus, microvascular or macrovascular disease and long duration worsen baseline arterial risk; with cigarette smoking at age $\\geq 35$ years, arterial event risk with estrogen is dose dependent; and with prior VTE, recurrence risk is modified by provoking factors, thrombophilia, and anticoagulation status.\n\nWhich of the following decision algorithms most accurately maps these comorbidities to USMEC categories for CHC and LNG-IUD?\n\nA. \n- Hypertension:\n  - CHC: adequately controlled or blood pressure $140$ to $159$/$90$ to $99$ $\\rightarrow$ Category $3$; blood pressure $\\geq 160$ or $\\geq 100$, or with vascular disease $\\rightarrow$ Category $4$.\n  - LNG-IUD: adequately controlled or blood pressure $140$ to $159$/$90$ to $99$ $\\rightarrow$ Category $1$; blood pressure $\\geq 160$ or $\\geq 100$, or with vascular disease $\\rightarrow$ Category $2$.\n- Diabetes mellitus:\n  - CHC: no vascular disease and duration $< 20$ years $\\rightarrow$ Category $2$; microvascular or macrovascular disease or duration $\\geq 20$ years $\\rightarrow$ Category $3$ or $4$.\n  - LNG-IUD: any diabetes, with or without vascular disease, any duration $\\rightarrow$ Category $2$.\n- History of VTE (deep vein thrombosis or pulmonary embolism):\n  - CHC: not on anticoagulation and lower-risk history (provoked without ongoing risk) $\\rightarrow$ Category $3$; not on anticoagulation and higher-risk history (unprovoked, estrogen-associated, known thrombophilia, or recurrent) $\\rightarrow$ Category $4$; on therapeutic anticoagulation $\\rightarrow$ Category $3$.\n  - LNG-IUD: history of VTE or current anticoagulation $\\rightarrow$ Category $2$.\n- Cigarette smoking at age $\\geq 35$ years:\n  - CHC: $< 15$ cigarettes per day $\\rightarrow$ Category $3$; $\\geq 15$ cigarettes per day $\\rightarrow$ Category $4$.\n  - LNG-IUD: any smoking amount $\\rightarrow$ Category $1$.\n\nB.\n- Hypertension:\n  - CHC: adequately controlled $\\rightarrow$ Category $2$; blood pressure $140$ to $159$/$90$ to $99$ $\\rightarrow$ Category $2$; blood pressure $\\geq 160$ or $\\geq 100$ $\\rightarrow$ Category $3$; vascular disease $\\rightarrow$ Category $3$.\n  - LNG-IUD: any hypertension $\\rightarrow$ Category $3$.\n- Diabetes mellitus:\n  - CHC: no vascular disease $\\rightarrow$ Category $2$; vascular disease or duration $\\geq 20$ years $\\rightarrow$ Category $3$.\n  - LNG-IUD: vascular disease or duration $\\geq 20$ years $\\rightarrow$ Category $3$.\n- History of VTE:\n  - CHC: any history $\\rightarrow$ Category $3$.\n  - LNG-IUD: any history $\\rightarrow$ Category $3$.\n- Cigarette smoking at age $\\geq 35$ years:\n  - CHC: any amount $\\rightarrow$ Category $3$.\n  - LNG-IUD: any amount $\\rightarrow$ Category $2$.\n\nC.\n- Hypertension:\n  - CHC: adequately controlled $\\rightarrow$ Category $2$; blood pressure $140$ to $159$/$90$ to $99$ $\\rightarrow$ Category $3$; blood pressure $\\geq 160$ or $\\geq 100$ or vascular disease $\\rightarrow$ Category $3$.\n  - LNG-IUD: any hypertension $\\rightarrow$ Category $2$.\n- Diabetes mellitus:\n  - CHC: any diabetes $\\rightarrow$ Category $3$.\n  - LNG-IUD: any diabetes $\\rightarrow$ Category $1$.\n- History of VTE:\n  - CHC: on therapeutic anticoagulation $\\rightarrow$ Category $2$; not on anticoagulation $\\rightarrow$ Category $3$.\n  - LNG-IUD: any history $\\rightarrow$ Category $3$.\n- Cigarette smoking at age $\\geq 35$ years:\n  - CHC: any amount $\\rightarrow$ Category $4$.\n  - LNG-IUD: any amount $\\rightarrow$ Category $1$.\n\nD.\n- Hypertension:\n  - CHC: adequately controlled or blood pressure $140$ to $159$/$90$ to $99$ $\\rightarrow$ Category $2$; blood pressure $\\geq 160$ or $\\geq 100$ $\\rightarrow$ Category $4$; vascular disease $\\rightarrow$ Category $4$.\n  - LNG-IUD: adequately controlled $\\rightarrow$ Category $1$; blood pressure $\\geq 160$ or $\\geq 100$ or vascular disease $\\rightarrow$ Category $3$.\n- Diabetes mellitus:\n  - CHC: no vascular disease and duration $< 20$ years $\\rightarrow$ Category $1$; microvascular or macrovascular disease or duration $\\geq 20$ years $\\rightarrow$ Category $4$.\n  - LNG-IUD: no vascular disease $\\rightarrow$ Category $1$; microvascular or macrovascular disease $\\rightarrow$ Category $3$.\n- History of VTE:\n  - CHC: any history or current anticoagulation $\\rightarrow$ Category $4$.\n  - LNG-IUD: any history or current anticoagulation $\\rightarrow$ Category $3$.\n- Cigarette smoking at age $\\geq 35$ years:\n  - CHC: $< 15$ cigarettes per day $\\rightarrow$ Category $2$; $\\geq 15$ cigarettes per day $\\rightarrow$ Category $3$.\n  - LNG-IUD: any amount $\\rightarrow$ Category $1$.\n\nSelect the single best algorithm.", "solution": "## PROBLEM VALIDATION\n\n### Step 1: Extract Givens\n\nThe problem provides the following data, definitions, and principles:\n\n- **USMEC Categories**:\n  - Category $1$: no restriction\n  - Category $2$: advantages generally outweigh theoretical or proven risks\n  - Category $3$: risks usually outweigh advantages\n  - Category $4$: unacceptable health risk\n\n- **Contraceptive Methods**:\n  - Combined hormonal contraception (CHC; estrogen-progestin)\n  - Levonorgestrel intrauterine device (LNG-IUD)\n\n- **Comorbidities**:\n  - Hypertension (HTN)\n  - Diabetes mellitus (DM)\n  - Venous thromboembolism (VTE), defined as deep vein thrombosis or pulmonary embolism\n  - Cigarette smoking at age $\\geq 35$ years\n\n- **Fundamental Principles**:\n  1. Estrogen-containing methods increase hepatic production of clotting factors and raise risks of venous and arterial thromboembolism.\n  2. Progestin-only intrauterine methods have minimal systemic effects.\n  3. Vascular disease increases baseline risk for myocardial infarction and stroke.\n  4. With hypertension, arterial event risk rises in proportion to the severity of blood pressure elevation.\n  5. With diabetes mellitus, microvascular or macrovascular disease and long duration worsen baseline arterial risk.\n  6. With cigarette smoking at age $\\geq 35$ years, arterial event risk with estrogen is dose dependent.\n  7. With prior VTE, recurrence risk is modified by provoking factors, thrombophilia, and anticoagulation status.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem is to construct a decision algorithm based on established medical facts and guidelines.\n\n- **Scientifically Grounded**: The problem is based on the real-world United States Medical Eligibility Criteria (USMEC) for Contraceptive Use, a framework developed by the CDC. The physiological principles provided (effects of estrogen, risk factors for thromboembolism) are fundamental and well-established in medicine. The problem does not contain pseudoscience or speculation.\n- **Well-Posed**: The task is to create a mapping from a set of conditions (comorbidities) to a set of categories (USMEC $1$-$4$) for two specific contraceptive types, using a given set of rules (the fundamental principles). This is a logical reasoning problem that is structured to have a unique, correct mapping based on the provided information.\n- **Objective**: The problem uses precise medical terminology and quantitative data where appropriate (e.g., blood pressure levels, age, number of cigarettes). The definitions and principles are stated objectively.\n\nThe problem statement is internally consistent, scientifically sound, and well-posed. There are no identifiable flaws.\n\n### Step 3: Verdict and Action\n\nThe problem statement is valid. I will proceed with the derivation of the solution.\n\n---\n\n## DERIVATION OF THE CORRECT ALGORITHM\n\nThe task is to apply the given fundamental principles to map the four comorbidities to USMEC categories for CHC and LNG-IUD.\n\n### 1. Hypertension (HTN)\n\n- **Principles**: Arterial event risk increases with HTN severity (Principle 4). Estrogen increases arterial risk (Principle 1). LNG-IUD has minimal systemic effects (Principle 2).\n- **CHC**: Combining CHC with HTN synergistically increases arterial risk.\n  - Mild or Adequately Controlled HTN: The baseline risk is elevated. Adding estrogen creates a situation where risks must be carefully weighed against benefits. A classification of Category $3$ (risks usually outweigh advantages) is medically prudent.\n  - Moderately elevated HTN (e.g., blood pressure $140-159$ mmHg systolic or $90-99$ mmHg diastolic): The risk is significantly increased. Category $3$ is appropriate.\n  - Severely elevated HTN (e.g., blood pressure $\\geq 160$ mmHg systolic or $\\geq 100$ mmHg diastolic) or HTN complicated by vascular disease: The baseline arterial risk is very high. Adding estrogen creates an unacceptable risk of stroke or myocardial infarction. This corresponds to Category $4$.\n- **LNG-IUD**: Due to its minimal systemic effects, the LNG-IUD does not affect blood pressure or arterial risk.\n  - For patients with HTN, it is a very safe option. For controlled or moderately elevated HTN without other complications, there is no restriction, which is Category $1$.\n  - In cases of very severe HTN or HTN with existing vascular disease, the patient is medically complex. While the device itself poses no risk to the HTN, any procedure or new medication in a critically ill patient warrants caution. Thus, classifying it as Category $2$ (advantages outweigh risks) reflects this clinical prudence, acknowledging the overall safety of the method itself.\n\n### 2. Diabetes Mellitus (DM)\n\n- **Principles**: DM with vascular disease or long duration ($\\geq 20$ years) increases arterial risk (Principle 5). Estrogen increases arterial risk (Principle 1). LNG-IUD has minimal systemic effects (Principle 2).\n- **CHC**:\n  - DM without vascular disease and shorter duration ($< 20$ years): The patient has an increased baseline cardiovascular risk. Adding estrogen requires a careful risk-benefit analysis. The advantages may still outweigh the risks. This is a classic Category $2$ situation.\n  - DM with established vascular disease (nephropathy, retinopathy, neuropathy) or long duration ($\\geq 20$ years): The baseline arterial risk is substantially elevated. The addition of estrogen significantly increases this risk, such that risks likely outweigh advantages (Category $3$) or become unacceptable (Category $4$), depending on the severity of the end-organ damage.\n- **LNG-IUD**: The method does not have systemic metabolic or vascular effects.\n  - It is an excellent choice for patients with DM, regardless of duration or complications. Given the patient's underlying medical complexity, a classification of Category $2$ (advantages outweigh risks) is a safe and appropriate general rule, emphasizing its benefits in a patient for whom other methods may be risky.\n\n### 3. History of Venous Thromboembolism (VTE)\n\n- **Principles**: History of VTE confers a risk of recurrence, which is modified by various factors (Principle 7). Estrogen increases venous thromboembolic risk (Principle 1). LNG-IUD has minimal systemic effects (Principle 2).\n- **CHC**: There is a direct and dangerous interaction.\n  - Any history of VTE makes the use of estrogen-containing contraception risky.\n  - High-risk history (e.g., unprovoked VTE, known thrombophilia, estrogen-associated VTE): The risk of recurrence is high, and adding estrogen creates an unacceptable risk. This is Category $4$.\n  - Low-risk history (e.g., a single VTE provoked by a resolved factor like major surgery): The risk of recurrence is lower but not zero. Adding estrogen is still ill-advised; the risks usually outweigh the advantages. This is Category $3$.\n  - On therapeutic anticoagulation: The anticoagulant provides protection, but starting a prothrombotic agent (estrogen) in this context is complex and still carries risk. The consensus is that risks usually outweigh advantages, making it Category $3$.\n- **LNG-IUD**: The method has no systemic effect on coagulation.\n  - It is a very safe method for patients with a current or past VTE. For a patient with such a serious medical condition (especially if on anticoagulation, which can increase procedural bleeding risk), classification as Category $2$ (advantages outweigh risks) is appropriate. It is a preferred method in this population.\n\n### 4. Cigarette Smoking at Age $\\geq 35$ Years\n\n- **Principles**: Arterial risk from estrogen is dose-dependent in smokers $\\geq 35$ years old (Principle 6). Estrogen increases arterial risk (Principle 1). LNG-IUD has minimal systemic effects (Principle 2).\n- **CHC**: The combination of age, smoking, and estrogen synergistically increases the risk of myocardial infarction and stroke.\n  - Light smoking ($< 15$ cigarettes/day) at age $\\geq 35$: The combined risk is significant. The risks are considered to usually outweigh the advantages. This is Category $3$.\n  - Heavy smoking ($\\geq 15$ cigarettes/day) at age $\\geq 35$: The combined risk is unacceptably high. This is a classic contraindication and is Category $4$.\n- **LNG-IUD**: The method has no systemic cardiovascular effects and does not interact with the risks of smoking.\n  - It is an unrestricted method for smokers. This is Category $1$.\n\n## OPTION-BY-OPTION ANALYSIS\n\nBased on the derived algorithm, we now evaluate the given options.\n\n**A. This option presents the following mappings:**\n- **Hypertension**: Matches our derivation. CHC is Cat 3 for moderate and Cat 4 for severe HTN/vascular disease. LNG-IUD is Cat 1 for moderate and Cat 2 for severe HTN/vascular disease.\n- **Diabetes mellitus**: Matches our derivation. CHC is Cat 2 for uncomplicated/short-duration and Cat 3/4 for complicated/long-duration. LNG-IUD is Cat 2 for any diabetes.\n- **History of VTE**: Matches our derivation. CHC is stratified as Cat 3 or Cat 4 based on risk profile and anticoagulation status. LNG-IUD is Cat 2.\n- **Cigarette smoking at age $\\geq 35$ years**: Matches our derivation. CHC is Cat 3 for $< 15$ cigarettes/day and Cat 4 for $\\geq 15$ cigarettes/day. LNG-IUD is Cat 1.\n**Verdict: Correct.** This algorithm is a detailed and accurate application of the provided first principles.\n\n**B. This option presents the following mappings:**\n- **Hypertension**: For CHC, it incorrectly assigns Cat 3 to severe HTN (should be Cat 4). For LNG-IUD, it incorrectly assigns Cat 3 (risks outweigh advantages), which contradicts the principle of minimal systemic effects and clinical practice where LNG-IUD is a preferred method.\n- **History of VTE**: For LNG-IUD, it incorrectly assigns Cat 3.\n**Verdict: Incorrect.** This option contains several significant errors, particularly in underestimating the risk of severe HTN with CHC and drastically overestimating the risk of LNG-IUDs.\n\n**C. This option presents the following mappings:**\n- **Hypertension**: For CHC, it incorrectly assigns Cat 3 to severe HTN with or without vascular disease (should be Cat 4).\n- **Diabetes mellitus**: For CHC, it oversimplifies by assigning Cat 3 to \"any diabetes,\" failing to distinguish uncomplicated cases (which are Cat 2).\n- **History of VTE**: For CHC, it incorrectly classifies use while on anticoagulation as Cat 2 (should be Cat 3). For LNG-IUD, it incorrectly assigns Cat 3 (should be Cat 2).\n- **Cigarette smoking**: For CHC, it incorrectly assigns Cat 4 to any amount of smoking, failing to distinguish light smokers (who are Cat 3).\n**Verdict: Incorrect.** This option contains numerous misclassifications and oversimplifications.\n\n**D. This option presents the following mappings:**\n- **Hypertension**: For LNG-IUD, it incorrectly assigns Cat 3 to severe HTN (should be Cat 2).\n- **Diabetes mellitus**: For CHC, it incorrectly assigns Cat 1 to uncomplicated DM. While low risk, it is not \"no restriction\" and should be Cat 2.\n- **History of VTE**: For CHC, it incorrectly assigns Cat 4 to all scenarios, including low-risk history and use with anticoagulation (which are Cat 3).\n- **Cigarette smoking**: For CHC, it incorrectly assigns Cat 3 to heavy smokers ($\\geq 15$/day), who should be Cat 4.\n**Verdict: Incorrect.** This option contains multiple errors in assigning risk categories.\n\n**CONCLUSION**\n\nOption A is the only algorithm that accurately and precisely maps the comorbidities to the correct USMEC categories based on the provided fundamental principles. It correctly captures the nuances of risk stratification based on severity, duration, dose-dependence, and other modifying factors.", "answer": "$$\\boxed{A}$$", "id": "4819644"}, {"introduction": "Effective patient counseling requires translating statistical data into meaningful comparisons that facilitate shared decision-making. This exercise [@problem_id:4819703] focuses on quantifying the real-world difference in effectiveness between two contraceptive methods using the concepts of Absolute Risk Reduction ($ARR$) and Number Needed to Treat ($NNT$). These metrics are invaluable tools for helping a patient understand the tangible benefit of choosing a more effective option.", "problem": "A patient in an internal medicine clinic seeks counseling on contraception. She currently uses a method with a typical-use failure rate of $0.07$ per person-year and is considering switching to a method with a typical-use failure rate of $0.005$ per person-year. For this counseling scenario, interpret the typical-use failure rate as the probability of pregnancy over a one-year horizon under real-world adherence. Using the accepted definitions of Absolute Risk Reduction (ARR) and Number Needed to Treat (NNT), compute the reduction in the one-year probability of pregnancy when switching methods and the corresponding NNT for preventing one pregnancy over one year through this switch. Express the ARR as a decimal and the NNT as an exact fraction in lowest terms. Do not use percentage signs, and do not include any units in your final values.", "solution": "The problem is first subjected to validation.\n\n### Step 1: Extract Givens\n-   Typical-use failure rate of the current contraceptive method: $0.07$ per person-year.\n-   Typical-use failure rate of the new contraceptive method: $0.005$ per person-year.\n-   Definition: The typical-use failure rate is to be interpreted as the probability of pregnancy over a one-year horizon.\n-   Objective: Compute the Absolute Risk Reduction (ARR) and the Number Needed to Treat (NNT).\n-   Output format for ARR: decimal.\n-   Output format for NNT: exact fraction in lowest terms.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientific Grounding**: The problem is scientifically grounded. The scenario describes a standard clinical counseling situation in internal medicine. The concepts of \"typical-use failure rate,\" \"Absolute Risk Reduction (ARR),\" and \"Number Needed to Treat (NNT)\" are fundamental, well-defined metrics in epidemiology and evidence-based medicine. The numerical values provided for the failure rates ($0.07$ and $0.005$) are realistic for existing contraceptive methods (e.g., corresponding to the typical-use one-year failure probabilities of birth control pills and an intrauterine device (IUD), respectively).\n2.  **Well-Posedness**: The problem is well-posed. It provides all necessary data and definitions to arrive at a unique solution. The definitions of ARR and NNT are standard and unambiguous.\n3.  **Objectivity**: The language is objective and precise, presenting a quantitative task based on given data without subjective or opinion-based elements.\n4.  **Completeness and Consistency**: The problem is self-contained and free of contradictions. The interpretation of failure rate as a one-year probability is explicitly stated, removing ambiguity.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid** as it is scientifically grounded, well-posed, and objective. A solution will now be derived.\n\n### Solution Derivation\n\nThe problem requires the calculation of two standard epidemiological measures: Absolute Risk Reduction (ARR) and Number Needed to Treat (NNT).\n\nLet $P_{current}$ be the probability of the adverse outcome (pregnancy) for a patient using the current method over a one-year horizon. This is the event rate in the control or baseline group.\nFrom the problem statement,\n$$P_{current} = 0.07$$\n\nLet $P_{new}$ be the probability of the adverse outcome (pregnancy) for a patient who switches to the new method over a one-year horizon. This is the event rate in the treatment or intervention group.\nFrom the problem statement,\n$$P_{new} = 0.005$$\n\nThe Absolute Risk Reduction (ARR) is defined as the absolute difference in the event rates between the control group and the treatment group. It quantifies the reduction in risk attributable to the intervention.\n$$ARR = P_{control} - P_{treatment}$$\nIn this context, the \"control\" is the current method and the \"treatment\" is the new method.\n$$ARR = P_{current} - P_{new}$$\nSubstituting the given values:\n$$ARR = 0.07 - 0.005 = 0.065$$\nThe problem specifies that the ARR should be expressed as a decimal, which it is.\n\nThe Number Needed to Treat (NNT) is the reciprocal of the Absolute Risk Reduction. It represents the average number of patients who must receive the treatment (switch to the new method) for a specific duration (one year) to prevent one additional adverse outcome (one pregnancy).\n$$NNT = \\frac{1}{ARR}$$\nUsing the calculated value of ARR:\n$$NNT = \\frac{1}{0.065}$$\nThe problem requires the NNT to be expressed as an exact fraction in lowest terms. To do this, we convert the decimal to a fraction:\n$$0.065 = \\frac{65}{1000}$$\nTherefore,\n$$NNT = \\frac{1}{\\frac{65}{1000}} = \\frac{1000}{65}$$\nTo reduce this fraction to its lowest terms, we find the greatest common divisor of the numerator and the denominator. Both $1000$ and $65$ are divisible by $5$.\n$$\\frac{1000 \\div 5}{65 \\div 5} = \\frac{200}{13}$$\nThe number $13$ is a prime number. Since $200$ is not a multiple of $13$ ($13 \\times 15 = 195$), the fraction $\\frac{200}{13}$ is in its lowest terms.\n\nThe two computed values are the ARR, which is $0.065$, and the NNT, which is $\\frac{200}{13}$. The final answer should be presented as a row matrix.", "answer": "$$\\boxed{\\begin{pmatrix} 0.065 & \\frac{200}{13} \\end{pmatrix}}$$", "id": "4819703"}, {"introduction": "The most challenging counseling situations often involve imperfect use of contraception, requiring a clinician to synthesize multiple variables to assess risk. This advanced problem [@problem_id:4819731] asks you to calculate the residual risk of pregnancy after a patient misses oral contraceptive pills and uses emergency contraception. This requires applying principles of reproductive physiology and pharmacology within a probabilistic framework to guide a patient through a common and anxious moment.", "problem": "A $26$-year-old patient using Combined Oral Contraceptive (COC) pills with previously regular $28$-day cycles reports missing $2$ consecutive active COC pills in week $1$ (days $1$ and $2$ of the active pills immediately following the hormone-free interval). She had a single episode of unprotected intercourse on the evening of day $2$, and took Levonorgestrel (LNG) Emergency Contraception (EC) $36$ hours after intercourse, within $72$ hours.\n\nModel the risk of pregnancy from first principles using the following scientifically grounded assumptions that align with day-specific fecundability and the law of total probability:\n\n- Loss of ovulation suppression after $2$ missed active COC pills in week $1$ occurs with probability $p_{\\mathrm{ov}}=0.60$.\n- Conditional on ovulation resuming, the time from intercourse to ovulation $T$ takes values in $\\{0,1,2,3,4,5\\}$ days, each with probability $1/6$.\n- Conditional day-specific fecundability given ovulation occurs is $f(0)=0.15$, $f(1)=0.32$, $f(2)=0.28$, $f(3)=0.20$, $f(4)=0.10$, $f(5)=0.04$.\n- LNG EC taken within $72$ hours reduces the risk of pregnancy by a constant relative risk reduction $R=0.58$ across the relevant fertile window.\n\nAssume independence of the EC effect from the distribution of $T$ within the stated window and ignore background conception risk outside the fertile window. Using the core definitions of conditional probability and risk reduction, derive the residual probability of pregnancy as a decimal. Round your final answer to four significant figures. Do not use a percentage sign.", "solution": "The problem requires the calculation of the residual probability of pregnancy for a patient under specific circumstances involving missed oral contraceptive pills and the use of emergency contraception. The calculation will be based on the law of total probability, using the provided scientifically-grounded assumptions and parameters.\n\nFirst, we must validate the problem statement.\n\n### Step 1: Extract Givens\n- Probability of loss of ovulation suppression after $2$ missed pills in week $1$: $p_{\\mathrm{ov}} = 0.60$.\n- Time from intercourse to ovulation, $T$, is a discrete random variable with sample space $\\{0, 1, 2, 3, 4, 5\\}$ days, conditional on ovulation occurring.\n- The probability mass function of $T$ is uniform: $P(T=t) = 1/6$ for each $t$ in the sample space.\n- The conditional day-specific fecundability (probability of pregnancy given intercourse occurred $t$ days before ovulation) is given by the function $f(t)$:\n  - $f(0) = 0.15$\n  - $f(1) = 0.32$\n  - $f(2) = 0.28$\n  - $f(3) = 0.20$\n  - $f(4) = 0.10$\n  - $f(5) = 0.04$\n- Levonorgestrel (LNG) Emergency Contraception (EC) was taken within the specified window ($36$ hours after intercourse, which is less than $72$ hours).\n- The relative risk reduction provided by LNG EC is $R = 0.58$.\n- All other sources of conception risk are to be ignored.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, drawing upon established principles of reproductive endocrinology and pharmacology, such as the mechanism of oral contraceptives, the concept of a fertile window, day-specific fecundability, and the efficacy of emergency contraception. The provided numerical values are plausible representations for a simplified biological model. The problem is well-posed, providing all necessary data and a clear objective. The language is objective and the assumptions, though simplifications, are explicitly stated, allowing for a unique, meaningful solution. There are no contradictions, ambiguities, or logical flaws. The problem asks for a quantitative risk assessment, a standard application of probability theory in medical science.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid. A solution will be derived.\n\n### Derivation of the Solution\nLet $P_{preg}$ be the total residual probability of pregnancy.\nLet $O$ be the event that ovulation occurs (i.e., loss of ovulation suppression).\nLet $O^c$ be the event that ovulation suppression is maintained.\nThe probability of $O$ is given as $P(O) = p_{\\mathrm{ov}} = 0.60$.\nThe probability of $O^c$ is therefore $P(O^c) = 1 - P(O) = 1 - 0.60 = 0.40$.\n\nUsing the law of total probability, the total probability of pregnancy can be expressed as:\n$$ P_{preg} = P(P_{preg} | O) P(O) + P(P_{preg} | O^c) P(O^c) $$\nIf ovulation suppression is maintained ($O^c$), pregnancy is not possible. Thus, the conditional probability of pregnancy given no ovulation is zero: $P(P_{preg} | O^c) = 0$.\nThe equation simplifies to:\n$$ P_{preg} = P(P_{preg} | O) P(O) $$\nHere, $P(P_{preg} | O)$ represents the probability of pregnancy given that ovulation occurs, and accounting for the use of emergency contraception.\n\nFirst, we must calculate the baseline probability of pregnancy given that ovulation occurs, but *before* considering the effect of emergency contraception. Let's denote this as $P_{preg, noEC} | O$. This probability depends on the timing of intercourse relative to ovulation, which is described by the random variable $T$. We apply the law of total probability again, summing over all possible values of $T$:\n$$ P_{preg, noEC} | O = \\sum_{t=0}^{5} P(P_{preg} | O, T=t) \\cdot P(T=t | O) $$\nFrom the problem statement:\n- The probability of pregnancy, given ovulation occurs and that intercourse was $t$ days prior, is the day-specific fecundability, $f(t)$. So, $P(P_{preg} | O, T=t) = f(t)$.\n- The probability of ovulation occurring $t$ days after intercourse, given ovulation happens at some point, is $P(T=t | O) = 1/6$.\n\nSubstituting these into the sum:\n$$ P_{preg, noEC} | O = \\sum_{t=0}^{5} f(t) \\cdot \\frac{1}{6} = \\frac{1}{6} \\sum_{t=0}^{5} f(t) $$\nNow, we calculate the sum of the fecundabilities:\n$$ \\sum_{t=0}^{5} f(t) = f(0) + f(1) + f(2) + f(3) + f(4) + f(5) $$\n$$ \\sum_{t=0}^{5} f(t) = 0.15 + 0.32 + 0.28 + 0.20 + 0.10 + 0.04 = 1.09 $$\nSo, the baseline probability of pregnancy, given ovulation, is:\n$$ P_{preg, noEC} | O = \\frac{1.09}{6} $$\nThis is the risk of pregnancy without emergency contraception. The patient, however, used LNG EC, which has a relative risk reduction of $R = 0.58$. The probability of pregnancy *with* EC is the baseline probability multiplied by a risk factor of $(1-R)$.\nTherefore, the term $P(P_{preg} | O)$ from our main equation is:\n$$ P(P_{preg} | O) = (P_{preg, noEC} | O) \\times (1 - R) $$\n$$ P(P_{preg} | O) = \\left( \\frac{1}{6} \\sum_{t=0}^{5} f(t) \\right) \\times (1 - R) $$\nNow we substitute this back into the equation for the total probability of pregnancy:\n$$ P_{preg} = \\left[ \\left( \\frac{1}{6} \\sum_{t=0}^{5} f(t) \\right) \\times (1 - R) \\right] \\times p_{\\mathrm{ov}} $$\nPlugging in all the numerical values:\n$$ P_{preg} = \\left[ \\left( \\frac{1.09}{6} \\right) \\times (1 - 0.58) \\right] \\times 0.60 $$\n$$ P_{preg} = \\left[ \\frac{1.09}{6} \\times 0.42 \\right] \\times 0.60 $$\n$$ P_{preg} = \\frac{1.09 \\times 0.42 \\times 0.60}{6} $$\n$$ P_{preg} = \\frac{0.27468}{6} $$\n$$ P_{preg} = 0.04578 $$\nThe problem asks for the final answer to be rounded to four significant figures. The calculated value $0.04578$ has exactly four significant figures ($4$, $5$, $7$, $8$), so no further rounding is necessary. Note that if we use fractions for intermediary steps: $P_{preg} = (\\frac{1.09}{6}) \\cdot (0.42) \\cdot (0.60) = (\\frac{1.09}{6}) \\cdot (0.252) = 1.09 \\cdot 0.042 = 0.04578$. If we evaluate $\\frac{1.09}{6}$ first, we get $0.181\\overline{6}$. Then $0.181\\overline{6} \\times 0.42 \\times 0.60 = 0.0763 \\times 0.60 = 0.04578$. The result is exact. If we use the repeating decimal notation:\n$$ P_{preg} = \\frac{1.09}{6} \\times 0.42 \\times 0.60 = 0.181666... \\times 0.252 = 0.04578 $$\nThe final result is $0.04578$.", "answer": "$$\n\\boxed{0.04578}\n$$", "id": "4819731"}]}